Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026

— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral Presentation —

— Detailed Positive Results From REVITALYZSM Phase 3 Study Evaluating LUMRYZ in Adults With Idiopathic Hypersomnia to be Shared in Oral Presentation —

Alkermes plc (NASDAQ:ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes’ sleep portfolio following the acquisition of Avadel Pharmaceuticals plc, and alixorexton, Alkermes’ novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).

In an oral presentation, the company will present findings from the Vibrance‑1 phase 2 study of alixorexton in adults with NT1, which were recently published in The Lancet Neurology. The presentation will also include data from the open-label, long-term extension study evaluating the safety and durability of effect in participants with NT1 and NT2 who received alixorexton for up to nine months of treatment.